Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Dexcom Inc (NASDAQ: DXCM) closed the day trading at $70.72 down -9.15% from the previous closing price of $77.84. In other words, the price has decreased by -$9.15 from its previous closing price. On the day, 8.34 million shares were traded.
Ratios:
For a better understanding of DXCM, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.71 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 43.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.28 and its Current Ratio is at 1.47. In the meantime, Its Debt-to-Equity ratio is 1.23 whereas as Long-Term Debt/Eq ratio is at 0.65.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Redburn Atlantic on February 03, 2025, Upgraded its rating to Buy and sets its target price to $115 from $85 previously.
On January 16, 2025, Robert W. Baird Upgraded its rating to Outperform which previously was Neutral and also upped its target price recommendation from $86 to $104.
Robert W. Baird Downgraded its Outperform to Neutral on July 26, 2024, whereas the target price for the stock was revised from $161 to $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 10 ’25 when JEREME SYLVAIN bought 7,000 shares for $73.83 per share.
Sylvain Jereme M sold 2,090 shares of DXCM for $181,650 on Jan 29 ’25. The EVP, Chief Financal Officer now owns 83,526 shares after completing the transaction at $86.91 per share. On Jan 29 ’25, another insider, Dolan Matthew Vincent, who serves as the EVP, Strategy & Corporate Dev of the company, sold 1,183 shares for $86.91 each. As a result, the insider received 102,820 and left with 42,044 shares of the company.
Valuation Measures:
As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.64, and their Forward P/E ratio for the next fiscal year is 28.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.85 while its Price-to-Book (P/B) ratio in mrq is 13.14.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $62.34. The 50-Day Moving Average of the stock is -16.25%, while the 200-Day Moving Average is calculated to be -16.87%.
Shares Statistics:
A total of 390.70M shares are outstanding, with a floating share count of 385.48M. Insiders hold about 1.35% of the company’s shares, while institutions hold 92.80% stake in the company.
